Health care company Eli Lilly and Company (NYSE: LLY) reported on Wednesday the receipt of the US Food and Drug Administration's (FDA) approval for Verzenio (abemaciclib) in combination with endocrine therapy (tamoxifen or an aromatase inhibitor) for the adjuvant treatment of certain people with breast cancer.
Specifically, the treatment was approved for adult patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-), node-positive, early breast cancer (EBC) at high risk of recurrence and a Ki-67 score of ≥20% as determined by an FDA-approved test. Ki-67 is a marker of cellular proliferation.
Verzenio is the first and only CDK4/6 inhibitor approved for this patient population, Eli Lilly said. It is available in tablet strengths of 200 mg, 150 mg, 100 mg and 50 mg.
Verzenio is already approved for the treatment of certain types of HR+ HER2- advanced or metastatic breast cancer. Concurrent with this latest approval, the FDA has expanded the use of Verzenio in all indications, when given in combination with endocrine therapy, to include men.
Scancell initiates SCOPE trial's iSCIB1+ cohort
Bio-Thera Solutions' BAT8006 phase II Study receives US FDA IND approval
Poseida Therapeutics names new chief medical officer
Biocytogen and ABL Bio collaborate on development of new bispecific antibody-drug conjugates
BioVaxys Technology announces non-brokered private placement
Senhwa Biosciences doses first subject in phase II study of Silmitasertib
Antennova completes first dosing cohort in Phase one study of ATN-031
M8 Pharmaceuticals collaborates with SERB Pharmaceuticals
BerGenBio ASA starts Phase 2a portion of BGBC016 clinical study of bemcentinib
Phanes Therapeutics receives FDA Fast Track designation for PT886